316
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Potential P-glycoprotein Pharmacokinetic Interaction of Telaprevir With Morphine or Methadone

, , , , &
Pages 261-267 | Accepted 08 May 2013, Published online: 24 Jul 2013

REFERENCES

  • Gatti DC, Cha A. Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection. Am J Health Syst Pharm. 2012;69:2062–2065.
  • Fudin J, Fontenelle DV, Payne A. Rifampin reduces oral morphine absorption: a case of transdermal buprenorphine selection based on morphine pharmacokinetics. Pain Palliat Care Pharmacother. 2012;26:362–367.
  • Taylor LE, Holubar M, Wu K, Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis. 2011;52:812–818.
  • Taylor LE, Swan T. Mayer KH. HIV coinfection with hepatitis c virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012; 55(Suppl 1):S33.
  • Centers for Disease Control and Prevention, Division of Viral Hepatitis and National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. HIV/AIDS and viral hepatitis. Available at: http://www.cdc.gov/hepatitis/Populations/hiv.htm. Accessed February 2, 2012.
  • Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison population is cost-saving. Hepatology. 2008;48:1387–1395.
  • Hanson D. No methadone therapy for US prisoners. The Fix. May 3, 2011. Available at: http://www.thefix.com/content/no-methadone-therapy-us-prisoners
  • Klevens RM, Hu DJ, Jiles R, Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. 2012; 55(Suppl 1):S3–S9.
  • Telaprevir. Lexi-Drugs Online. Hudson, OH: Lexi-Comp; 2007. Available at: http://online.lexi.com [subscription required to view]. Accessed January 16, 2013.
  • Center for Disease Control and Prevention. Hepatitis C information for health professionals. September 2002. Available at: http://www.cdc.gov/idu/hepatitis/hepc_and_hiv_co.pdf. Accessed January 16, 2013.
  • Scimeca HM, Savage SR, Portenoy R, Lowinson J. Treatment of pain in methadone-maintained patients. Mt Sinai J Med. 2000; 67:412–422.
  • Jain R, Jain S. Antidepressants in the treatment of chronic pain. Pract Pain Manage. 2011; 11(2). Available at: http://www. practicalpainmanagement.com/treatments/pharmacological/ non-opioids/antidepressants-treatment-chronic-pain. Accessed January 16, 2013.
  • Mercer S, Coop A. Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance. Curr Top Med Chem. 2011;11:1157–1164.
  • Baumann TJ, Strickland JM, Herndon CM. Pain management. In: Talbert RL, DiPiro JT, Matke GR. Posey LM, Wells BG, Yee GC, eds. Pharmacotherapy: A Pathophysiological Approach. 8th ed. New York: McGraw-Hill; 2011: 989–989.
  • Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. In: Chabner BA, Brunton LL, Knollmann BC, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-HIll Professional; 2011: 481–526. Available at: http://www.accesspharmacy.com/ content.aspx?aID=16663974. Accessed January 16, 2013.
  • Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone. Implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41:1153–1193.
  • Van Heeswijk R, Vandevoorde A, Verboven P, The pharmacokinetic interaction between methadone and the investigation HCV protease inhibitor telaprevir. J Clin Pharmacol. 2012;52:1574–1583.
  • Virani A, Mailis A, Shapiro LE, Sher NH. Drug interaction in human neuropathic pain pharmacotherapy. Pain. 1997;73: 3–13.
  • McPherson ML. Methadone: a complex and challenging analgesic, but its worth it! Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing. [Edition if not first.] Bethesda, MD: American Society of Health-System Pharmacists; 2010:107–111.
  • Johnson, J. Methadone. 2005. Available at: http://pubs.acs.org/ cen/coverstory/83/8325/8325methadone.html. Accessed December 31, 2012.
  • Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother. 2005;19:13–24.
  • Kristensen K, Christensen CB, Christup LL. The mu1, mu2, delta, kappa opiod receptor binding profiles of methadone stereoisomers and morphine. Life Sci (Life Sciences). 1995;56: 45–50.
  • Yang F, Tong X, McCarver DG, Hines RN, Beard DA. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn. 2006;33:485–518.
  • Fonseca F, de la Torre R, Díaz L, Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS ONE 2011;6:e19527. doi: 10.1371/journal.pone.0019527.
  • Bruggermann RJM, Alffenaar JC, Blijlevens NMA. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441–1458.
  • Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther. 2008;12: 109–124.
  • Hoffmeyer S, Burk O, von Richter O, Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473–3478.
  • Li L, Meier PJ, Ballatori N. Oatp2 mediates bidirectional organic solute transport: a role for intracellular glutathione. Mol Pharmacol. 2000;58:335–340.
  • Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41:1153–1193.
  • Vertex Pharmaceuticals Incorporated. Incivek (telaprevir). Highlights of prescribing information. December 2012. Available at: http://pi.vrtx.com/files/uspi_telaprevir.pdf. Accessed 31 December 2012.
  • Victrelis (Boceprevir) [package insert]. Whitehouse Station, NJ: Schering Corporation; 2011.
  • Centers for Disease Control and Prevention. Vital signs: risk for overdose from methadone used for pain relief. 2012. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6126a5. htm?s_cid=mm6126a5_w. Accessed January 31, 2013.
  • Coffman BL, Kearney WR, Green MD, Lowery RG, Tephly TR. Analysis of opioid binding to UDP-gluronosyltranferase 2B7 fusion proteins using nuclear magnetic resonance spectroscopy. Mol Pharmacol. 2001;69:1464–1469.
  • Miemi Pasanen MK, Neuvonen PJ. Organic anion transporter polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011;63:157–181.
  • Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev. 2008;20:553–624.
  • Morphine Sulfate (Morphine) [package insert]. Deerfield, IL: Baxter Healthcare Corporation; 2010.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.